Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$35.10M+5092.60%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gerard J. Michel
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 156
- Beta
- 0.60
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 24.51
Financials
Revenue
$35.10M+5092.6%Net Income
$6.95MEBITDA
$7.97MFree Cash Flow
$6.92MEPS (diluted)
$0.17Shares Outstanding (diluted)
41.02M+218788478812534.9%Operating Expenses
$24.07MCash & Debt
$104.31MReturn of Capital
$0.00Revenue by Segment (annual)
$2.06MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $85.23M | $2.70M | $0.08 |
| 2024 | $37.20M | $-26.39M | $-0.93 |
| 2023 | $2.06M | $-47.68M | $-2.94 |
| 2022 | $2.72M | $-36.51M | $-4.12 |
| 2021 | $3.56M | $-25.65M | $-3.59 |
| 2020 | $1.65M | $-24.16M | $-8.35 |
| 2019 | $1.58M | $-8.88M | $-342.82 |
| 2018 | $3.41M | $-19.22M | $-503846.14 |
| 2017 | $2.71M | $-45.12M | $-2275919775.64 |
| 2016 | $1.99M | $-17.97M | $-452622931118.73 |
| 2015 | $1.75M | $-14.70M | $-457509240140.24 |
| 2014 | $1.07M | $-17.38M | $-599153734148.44 |
| 2013 | $790.0K | $-30.32M | $-1238626350763.12 |
| 2012 | $346.0K | $-51.87M | $-26545751109293.85 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.11
- Implied price
- $1.99
- Return from $20.58
- -37.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.99 — -95.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -47.5% | -45.1% | -43.1% | -41.3% | -39.7% |
| 3.0% | -44.9% | -42.3% | -40.2% | -38.3% | -36.7% |
| 8.0% | -42.2% | -39.5% | -37.3% | -35.3% | -33.6% |
| 13.0% | -39.5% | -36.8% | -34.4% | -32.3% | -30.5% |
| 18.0% | -36.8% | -34.0% | -31.5% | -29.4% | -27.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70-6.67%Social Signal Score
Mentions (9)
- Newszacks.com·9d ago·Positive
Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Delcath Systems, Inc. (DCTH) Q3 2026 Earnings Call Transcript Delcath Systems, Inc. (DCTH) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·13d ago·Positive
Delcath Systems Q3 Earnings Call Highlights Delcath Systems NASDAQ: DCTH reported record third-quarter revenue of $35.1 million, up 71% from a year earlier, as use of its HEPZATO KIT increased across U.S. treatment centers. The company also raised its full-year revenue outlook and reported higher net income and positive operating cash flow.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
…r 5% could be taken well; GMs may see a sequential dip but will rebound in Q4. Recent CHOPIN phase II trial success and expansion of active treatment centers enhance DCTH's growth prospects, with 24% topline growth expected in the medium term.
View source ↗ - Newszacks.com·86d ago·Positive
What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now? Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·86d ago·Positive
Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
View source ↗ - Newszacks.com·87d ago·Positive
Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 52.44%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newszacks.com·102d ago·Positive
Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
View source ↗ - Newszacks.com·103d ago·Positive
Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.10 per share
Typical surprise +118.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$0.17 vs $-0.09beat
- Thu, Aug 6$0.07 vs $-0.09beat
- Thu, May 7$-0.03 vs $-0.09beat
- Thu, Feb 26$-0.05 vs $-0.06beat
- Tue, Nov 4$0.02 vs $0.02beat
- Wed, Aug 6$0.07 vs $0.03beat
Estimates and results for DCTH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DCTH officers and directors.
- Bought
- $494k
- Sold
- —
7 trades
0 trades
- Pennell Sandrabought
- Michel Gerard Jbought
- Sylvester John Richardbought
- Michel Gerard Jbought
- Aharon Gilbought
- Salamon Steven A Jbought
- Rosalind Advisors, Inc.bought
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Roger Wayne Marshallhouse · KS01 · disclosed Aug 6, 2018 (423d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
